{"id":348131,"date":"2025-08-25T13:58:46","date_gmt":"2025-08-25T13:58:46","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-cardiol-therapeutics\/"},"modified":"2025-08-25T13:58:46","modified_gmt":"2025-08-25T13:58:46","slug":"how-to-buy-cardiol-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/","title":{"rendered":"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334126,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-348131","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Cardiol Therapeutics Inc. (CRDL) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu klinik a\u015famadaki biyoteknoloji \u015firketine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel hisse fiyat\u0131, ticaret stratejileri ve yat\u0131r\u0131m f\u0131rsatlar\u0131n\u0131 ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Cardiol Therapeutics Inc. (CRDL) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu klinik a\u015famadaki biyoteknoloji \u015firketine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel hisse fiyat\u0131, ticaret stratejileri ve yat\u0131r\u0131m f\u0131rsatlar\u0131n\u0131 ke\u015ffedin."},"intro":"Keskin kardiyovask\u00fcler t\u0131p alan\u0131na yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Cardiol Therapeutics Inc. (CRDL), bilimsel at\u0131l\u0131mlar\u0131n \u00f6nemli getirilerle sonu\u00e7lanabilece\u011fi heyecan verici biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n \u00f6n saflar\u0131n\u0131 temsil ediyor. Bu klinik a\u015famadaki \u015firket, d\u00fcnya \u00e7ap\u0131nda milyonlarca insan\u0131 etkileyen kalp hastal\u0131klar\u0131 i\u00e7in devrim niteli\u011finde tedaviler geli\u015ftiriyor. Bu t\u0131bbi yenilik hikayesinin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Keskin kardiyovask\u00fcler t\u0131p alan\u0131na yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Cardiol Therapeutics Inc. (CRDL), bilimsel at\u0131l\u0131mlar\u0131n \u00f6nemli getirilerle sonu\u00e7lanabilece\u011fi heyecan verici biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n \u00f6n saflar\u0131n\u0131 temsil ediyor. Bu klinik a\u015famadaki \u015firket, d\u00fcnya \u00e7ap\u0131nda milyonlarca insan\u0131 etkileyen kalp hastal\u0131klar\u0131 i\u00e7in devrim niteli\u011finde tedaviler geli\u015ftiriyor. Bu t\u0131bbi yenilik hikayesinin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Ticaret Stratejisi<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Cardiol Therapeutics Inc. (CRDL) hisseleri <strong>1,62 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor ve biyoteknoloji sekt\u00f6r\u00fcne ilgi duyan yat\u0131r\u0131mc\u0131lar i\u00e7in ilgi \u00e7ekici bir giri\u015f noktas\u0131 sunuyor. Hisse senedi son zamanlarda \u00f6nemli dalgalanmalar ya\u015fad\u0131, bu nedenle optimal giri\u015f i\u00e7in zamanlama kritik \u00f6neme sahip.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: Takviminize <strong>13 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin\u2014bu tarihte Cardiol Therapeutics bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayacak. Tarihsel veriler, bu duyurular\u0131n \u00f6nemli fiyat hareketlerini tetikleyebilece\u011fini g\u00f6steriyor.<\/p> <p>Son kazan\u00e7lar\u0131n etkisine bak\u0131ld\u0131\u011f\u0131nda, 14 A\u011fustos 2025 raporu klinik a\u015famadaki biyoteknoloji hisselerinin haberlere nas\u0131l tepki verdi\u011fini g\u00f6sterdi. \u015eirket, -0,07 $ EPS bildirdi ve -0,11 $ olan piyasa beklentisini %36 oran\u0131nda a\u015ft\u0131 (<a href=\"https:\/\/public.com\/stocks\/crdl\/earnings\">2025 2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>). Bu olumlu s\u00fcrpriz genellikle yukar\u0131 y\u00f6nl\u00fc ivme yarat\u0131r, ancak hissenin y\u00fcksek volatilitesi nedeniyle tepkiler \u00f6ng\u00f6r\u00fclemez olabilir.<\/p> <h3>Son Fiyat Performans\u0131 Analizi<\/h3> <p>Son alt\u0131 ayda, CRDL klinik a\u015famadaki biyoteknoloji hisselerine \u00f6zg\u00fc bir ini\u015f \u00e7\u0131k\u0131\u015f paterni g\u00f6sterdi:<\/p> <ul> <li><strong>\u015eubat-Mart 2025<\/strong>: \u015eirketin Faz II denemelerini ilerletmesiyle hisse 1,70-1,90 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li> <li><strong>Nisan 2025<\/strong>: Daha geni\u015f piyasa biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k nedeniyle yakla\u015f\u0131k 1,45 $ seviyesine d\u00fc\u015ft\u00fc<\/li> <li><strong>May\u0131s 2025<\/strong>: Olumlu klinik deneme beklentisiyle 1,85 $ seviyesine toparland\u0131<\/li> <li><strong>Haziran-Temmuz 2025<\/strong>: Deneme sonu\u00e7lar\u0131n\u0131 beklerken 1,60-1,75 $ aras\u0131nda konsolide oldu<\/li> <li><strong>A\u011fustos 2025<\/strong>: Kazan\u00e7 sonras\u0131 1,62 $ seviyesinde, piyasa volatilitesine ra\u011fmen diren\u00e7 g\u00f6steriyor<\/li> <\/ul> <p>Hissenin 1,70 beta de\u011feri, genel piyasadan %70 daha fazla dalgalanma g\u00f6sterdi\u011fini belirtir (<a href=\"https:\/\/marketchameleon.com\/Overview\/CRDL\/Summary\/\">Piyasa Volatilite Verileri<\/a>). Bu volatilite, hem risk hem de f\u0131rsat yarat\u0131r.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve klinik geli\u015fim kilometre ta\u015flar\u0131na dayanarak, CRDL i\u00e7in gelecekte neler olabilece\u011fine dair \u00f6ng\u00f6r\u00fcler:<\/p> <p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 2,50-3,00 $ (y\u00fczde 54-85 y\u00fckseli\u015f potansiyeli)<\/p> <ul> <li>Faz II denemelerindeki ilerleme ve potansiyel ortakl\u0131k duyurular\u0131 taraf\u0131ndan destekleniyor<\/li> <\/ul> <p><strong>2026 Tahmini<\/strong>: 4,00-5,00 $<\/p> <ul> <li>Faz II ba\u015far\u0131yla tamamlan\u0131p Faz III ba\u015flat\u0131lmas\u0131 varsay\u0131m\u0131yla<\/li> <\/ul> <p><strong>2028 Projeksiyonu<\/strong>: 6,00-8,00 $<\/p> <ul> <li>\u00d6nc\u00fc aday CardiolRx\u2122 i\u00e7in FDA onay s\u00fcreci olas\u0131l\u0131\u011f\u0131<\/li> <\/ul> <p><strong>2030 Uzun Vadeli Vizyon<\/strong>: 10,00 $ ve \u00fczeri<\/p> <ul> <li>Ticarile\u015fme ba\u015far\u0131s\u0131 ve \u00fcr\u00fcn hatt\u0131 geni\u015flemesi<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: 3-5 y\u0131ll\u0131k ufku olan risk toleransl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Mevcut fiyat, b\u00fcy\u00fck klinik kataliz\u00f6rlerden \u00f6nce cazip bir giri\u015f noktas\u0131 sunuyor.<\/p> <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Potansiyel Riskler:<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 Riski<\/strong>: Faz II\/III denemeleri olumsuz sonu\u00e7lar g\u00f6sterebilir<\/li> <li><strong>Nakit T\u00fcketim Endi\u015feleri<\/strong>: \u015eirket 2025 2. \u00e7eyrekte 8,35 milyon $ net zarar bildirdi, nakit 30,6 milyon $'dan 18,2 milyon $'a d\u00fc\u015ft\u00fc (<a href=\"https:\/\/www.ainvest.com\/news\/cardiol-therapeutics-reports-q2-2025-financial-results-rising-losses-ongoing-investments-research-development-2508\/\">Finansal Analiz<\/a>)<\/li> <li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA onay s\u00fcrecindeki belirsizlikler<\/li> <li><strong>Piyasa Volatilitesi<\/strong>: 1,70 y\u00fcksek beta, piyasa dalgalanmalar\u0131n\u0131 art\u0131r\u0131r<\/li> <li><strong>Hisse Seyrelme Riski<\/strong>: Operasyonlar\u0131 finanse etmek i\u00e7in gelecekte olas\u0131 hisse arzlar\u0131<\/li> <\/ul> <h3>2025 \u0130\u00e7in Olumlu Kataliz\u00f6rler:<\/h3> <ul> <li><strong>Faz II Ba\u015far\u0131s\u0131<\/strong>: ARCHER denemesi, akut miyokarditte ekstrasel\u00fcler hacimde anlaml\u0131 iyile\u015fme g\u00f6sterdi (p = 0,0538) (<a href=\"https:\/\/www.cardiolrx.com\/cardiol-therapeutics-announces-topline-results-from-the-phase-ii-archer-trial-of-cardiolrx-in-acute-myocarditis\/\">Deneme Sonu\u00e7lar\u0131<\/a>)<\/li> <li><strong>Yetim \u0130la\u00e7 Stat\u00fcs\u00fc<\/strong>: CardiolRx\u2122 perikardit i\u00e7in bu stat\u00fcy\u00fc ald\u0131, piyasa m\u00fcnhas\u0131rl\u0131\u011f\u0131 sa\u011fl\u0131yor<\/li> <li><strong>Analist \u0130yimserli\u011fi<\/strong>: Ortalama fiyat hedefi 8,00-9,00 $ aras\u0131, %400-455 y\u00fckseli\u015f potansiyeli (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/CRDL\/forecast\/\">Analist Hedefleri<\/a>)<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Kardiyovask\u00fcler inflamasyon tedavilerine artan odaklanma<\/li> <li><strong>G\u00fc\u00e7l\u00fc Y\u00f6netim<\/strong>: Son hissedar oylamalar\u0131nda t\u00fcm y\u00f6netim kurulu adaylar\u0131 %92'nin \u00fczerinde onay ald\u0131<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2> <p><strong>\u015eu anda ne yapmal\u0131s\u0131n\u0131z?<\/strong> \u0130\u015fte profesyonel tavsiyem:<\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-3'\u00fcn\u00fc CRDL'ye ay\u0131r\u0131n\u2014bu y\u00fcksek riskli bir biyoteknoloji yat\u0131r\u0131m\u0131d\u0131r<\/li> <li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: Giri\u015f fiyat\u0131n\u0131z\u0131 ortalamak i\u00e7in birka\u00e7 hafta i\u00e7inde par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li> <li><strong>Zarar Durdur Emirleri Koyun<\/strong>: Sermayenizi korumak i\u00e7in %15-20 zarar durdur emirleri belirleyin<\/li> <li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: Kas\u0131m kazan\u00e7lar\u0131 ve klinik deneme g\u00fcncellemelerini izleyin<\/li> <\/ol> <p><strong>Esprili deneyimli yat\u0131r\u0131mc\u0131 bilgeli\u011fi<\/strong>: \"CRDL gibi biyoteknoloji hisseleriyle i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar, aralarda radyo sessizli\u011fi ve ara s\u0131ra patlay\u0131c\u0131 tepkiler. Her zaman acil \u00e7\u0131k\u0131\u015f stratejiniz olsun!\"<\/p> <h2>\u2705 Ad\u0131m Ad\u0131m: Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ listeleri ve biyoteknoloji hisseleri sunan bir platform se\u00e7in<\/td><\/tr> <tr><td>2<\/td><td>Hesap Do\u011frulamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Uyumluluk i\u00e7in gerekli belgeleri sa\u011flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td><td>Risk alabilece\u011finiz y\u00f6netilebilir bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>CRDL'yi \u0130yi Ara\u015ft\u0131r\u0131n<\/td><td>\u015eirketin \u00fcr\u00fcn hatt\u0131n\u0131 ve risklerini anlay\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Limit Emri Verin<\/td><td>Fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td><\/tr> <tr><td>6<\/td><td>Pozisyonunuzu Takip Edin<\/td><td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td><\/tr> <tr><td>7<\/td><td>D\u00fczenli Olarak G\u00f6zden Ge\u00e7irin<\/td><td>Yat\u0131r\u0131m tezini \u00fc\u00e7 ayda bir yeniden de\u011ferlendirin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option'\u0131n \u00dcst\u00fcnl\u00fckleri<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, CRDL gibi hisselerde i\u015flem yapmak i\u00e7in ola\u011fan\u00fcst\u00fc avantajlar sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $\u2014stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Herhangi bir resmi kimlik ile 1 dakikal\u0131k KYC s\u00fcreci<\/li> <li><strong>\u00c7ekim Se\u00e7enekleri<\/strong>: Kripto, e-c\u00fczdanlar ve banka kartlar\u0131 dahil 100'den fazla y\u00f6ntem<\/li> <li><strong>Kullan\u0131c\u0131 Dostu Platform<\/strong>: Yeni ba\u015flayanlar i\u00e7in tasarlanm\u0131\u015f sezgisel aray\u00fcz<\/li> <li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: Pocket Option blogunda kapsaml\u0131 \u00f6\u011frenme materyalleri<\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, biyoteknoloji hisse ticaretinin inceliklerini \u00f6\u011frenirken k\u00fc\u00e7\u00fck ba\u015flay\u0131p b\u00fcy\u00fcmek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025'te Cardiol Therapeutics: Yenilik Lideri<\/h2> <p>Cardiol Therapeutics, kardiyovask\u00fcler t\u0131p yenili\u011finin \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirket, milyonlarca insan\u0131 etkileyen ve s\u0131n\u0131rl\u0131 tedavi se\u00e7ene\u011fi bulunan kalp hastal\u0131klar\u0131 i\u00e7in anti-inflamatuar ve anti-fibrotik tedaviler geli\u015ftirmeye odaklan\u0131yor.<\/p> <p><strong>Mevcut Odak Alanlar\u0131<\/strong>:<\/p> <ul> <li>Akut miyokardit ve tekrarlayan perikardit i\u00e7in CardiolRx\u2122<\/li> <li>Kalp yetmezli\u011fi i\u00e7in CRD-38 subkutan form\u00fclasyon<\/li> <li>Nadir kardiyak durumlar i\u00e7in yetim ila\u00e7 stat\u00fcs\u00fcndeki tedaviler<\/li> <\/ul> <p>\u015eirketin yak\u0131n zamanda tamamlanan Faz II ARCHER denemesi, FDA onayl\u0131 tedavisi olmayan akut miyokarditte umut verici etkinlik g\u00f6sterdi (<a href=\"https:\/\/thedeepdive.ca\/cardiol-therapeutics-releases-positive-topline-results-from-phase-ii-clinical-trial\/\">Klinik Geli\u015fim<\/a>). Bu, Cardiol'u hizmet verilmeyen bir pazarda potansiyel lider olarak konumland\u0131r\u0131yor.<\/p> <p><strong>\u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: 2025 y\u0131l\u0131nda Cardiol Therapeutics, k\u00fcresel tedarik zinciri zorluklar\u0131 s\u0131ras\u0131nda \u00e7ok uluslu bir Faz II denemesini ba\u015far\u0131yla tamamlayan az say\u0131daki biyoteknoloji \u015firketinden biri oldu; ABD, Fransa, Brezilya ve \u0130srail\u2019den hastalar kaydedildi ve \u00f6nemli gecikme ya\u015fanmad\u0131\u2014bu, klinik ara\u015ft\u0131rmadaki operasyonel m\u00fckemmeliyetlerinin bir kan\u0131t\u0131d\u0131r.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Ticaret Stratejisi<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Cardiol Therapeutics Inc. (CRDL) hisseleri <strong>1,62 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor ve biyoteknoloji sekt\u00f6r\u00fcne ilgi duyan yat\u0131r\u0131mc\u0131lar i\u00e7in ilgi \u00e7ekici bir giri\u015f noktas\u0131 sunuyor. Hisse senedi son zamanlarda \u00f6nemli dalgalanmalar ya\u015fad\u0131, bu nedenle optimal giri\u015f i\u00e7in zamanlama kritik \u00f6neme sahip.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: Takviminize <strong>13 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin\u2014bu tarihte Cardiol Therapeutics bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayacak. Tarihsel veriler, bu duyurular\u0131n \u00f6nemli fiyat hareketlerini tetikleyebilece\u011fini g\u00f6steriyor.<\/p>\n<p>Son kazan\u00e7lar\u0131n etkisine bak\u0131ld\u0131\u011f\u0131nda, 14 A\u011fustos 2025 raporu klinik a\u015famadaki biyoteknoloji hisselerinin haberlere nas\u0131l tepki verdi\u011fini g\u00f6sterdi. \u015eirket, -0,07 $ EPS bildirdi ve -0,11 $ olan piyasa beklentisini %36 oran\u0131nda a\u015ft\u0131 (<a href=\"https:\/\/public.com\/stocks\/crdl\/earnings\">2025 2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>). Bu olumlu s\u00fcrpriz genellikle yukar\u0131 y\u00f6nl\u00fc ivme yarat\u0131r, ancak hissenin y\u00fcksek volatilitesi nedeniyle tepkiler \u00f6ng\u00f6r\u00fclemez olabilir.<\/p>\n<h3>Son Fiyat Performans\u0131 Analizi<\/h3>\n<p>Son alt\u0131 ayda, CRDL klinik a\u015famadaki biyoteknoloji hisselerine \u00f6zg\u00fc bir ini\u015f \u00e7\u0131k\u0131\u015f paterni g\u00f6sterdi:<\/p>\n<ul>\n<li><strong>\u015eubat-Mart 2025<\/strong>: \u015eirketin Faz II denemelerini ilerletmesiyle hisse 1,70-1,90 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li>\n<li><strong>Nisan 2025<\/strong>: Daha geni\u015f piyasa biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k nedeniyle yakla\u015f\u0131k 1,45 $ seviyesine d\u00fc\u015ft\u00fc<\/li>\n<li><strong>May\u0131s 2025<\/strong>: Olumlu klinik deneme beklentisiyle 1,85 $ seviyesine toparland\u0131<\/li>\n<li><strong>Haziran-Temmuz 2025<\/strong>: Deneme sonu\u00e7lar\u0131n\u0131 beklerken 1,60-1,75 $ aras\u0131nda konsolide oldu<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: Kazan\u00e7 sonras\u0131 1,62 $ seviyesinde, piyasa volatilitesine ra\u011fmen diren\u00e7 g\u00f6steriyor<\/li>\n<\/ul>\n<p>Hissenin 1,70 beta de\u011feri, genel piyasadan %70 daha fazla dalgalanma g\u00f6sterdi\u011fini belirtir (<a href=\"https:\/\/marketchameleon.com\/Overview\/CRDL\/Summary\/\">Piyasa Volatilite Verileri<\/a>). Bu volatilite, hem risk hem de f\u0131rsat yarat\u0131r.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve klinik geli\u015fim kilometre ta\u015flar\u0131na dayanarak, CRDL i\u00e7in gelecekte neler olabilece\u011fine dair \u00f6ng\u00f6r\u00fcler:<\/p>\n<p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 2,50-3,00 $ (y\u00fczde 54-85 y\u00fckseli\u015f potansiyeli)<\/p>\n<ul>\n<li>Faz II denemelerindeki ilerleme ve potansiyel ortakl\u0131k duyurular\u0131 taraf\u0131ndan destekleniyor<\/li>\n<\/ul>\n<p><strong>2026 Tahmini<\/strong>: 4,00-5,00 $<\/p>\n<ul>\n<li>Faz II ba\u015far\u0131yla tamamlan\u0131p Faz III ba\u015flat\u0131lmas\u0131 varsay\u0131m\u0131yla<\/li>\n<\/ul>\n<p><strong>2028 Projeksiyonu<\/strong>: 6,00-8,00 $<\/p>\n<ul>\n<li>\u00d6nc\u00fc aday CardiolRx\u2122 i\u00e7in FDA onay s\u00fcreci olas\u0131l\u0131\u011f\u0131<\/li>\n<\/ul>\n<p><strong>2030 Uzun Vadeli Vizyon<\/strong>: 10,00 $ ve \u00fczeri<\/p>\n<ul>\n<li>Ticarile\u015fme ba\u015far\u0131s\u0131 ve \u00fcr\u00fcn hatt\u0131 geni\u015flemesi<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: 3-5 y\u0131ll\u0131k ufku olan risk toleransl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Mevcut fiyat, b\u00fcy\u00fck klinik kataliz\u00f6rlerden \u00f6nce cazip bir giri\u015f noktas\u0131 sunuyor.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Potansiyel Riskler:<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 Riski<\/strong>: Faz II\/III denemeleri olumsuz sonu\u00e7lar g\u00f6sterebilir<\/li>\n<li><strong>Nakit T\u00fcketim Endi\u015feleri<\/strong>: \u015eirket 2025 2. \u00e7eyrekte 8,35 milyon $ net zarar bildirdi, nakit 30,6 milyon $&#8217;dan 18,2 milyon $&#8217;a d\u00fc\u015ft\u00fc (<a href=\"https:\/\/www.ainvest.com\/news\/cardiol-therapeutics-reports-q2-2025-financial-results-rising-losses-ongoing-investments-research-development-2508\/\">Finansal Analiz<\/a>)<\/li>\n<li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA onay s\u00fcrecindeki belirsizlikler<\/li>\n<li><strong>Piyasa Volatilitesi<\/strong>: 1,70 y\u00fcksek beta, piyasa dalgalanmalar\u0131n\u0131 art\u0131r\u0131r<\/li>\n<li><strong>Hisse Seyrelme Riski<\/strong>: Operasyonlar\u0131 finanse etmek i\u00e7in gelecekte olas\u0131 hisse arzlar\u0131<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Olumlu Kataliz\u00f6rler:<\/h3>\n<ul>\n<li><strong>Faz II Ba\u015far\u0131s\u0131<\/strong>: ARCHER denemesi, akut miyokarditte ekstrasel\u00fcler hacimde anlaml\u0131 iyile\u015fme g\u00f6sterdi (p = 0,0538) (<a href=\"https:\/\/www.cardiolrx.com\/cardiol-therapeutics-announces-topline-results-from-the-phase-ii-archer-trial-of-cardiolrx-in-acute-myocarditis\/\">Deneme Sonu\u00e7lar\u0131<\/a>)<\/li>\n<li><strong>Yetim \u0130la\u00e7 Stat\u00fcs\u00fc<\/strong>: CardiolRx\u2122 perikardit i\u00e7in bu stat\u00fcy\u00fc ald\u0131, piyasa m\u00fcnhas\u0131rl\u0131\u011f\u0131 sa\u011fl\u0131yor<\/li>\n<li><strong>Analist \u0130yimserli\u011fi<\/strong>: Ortalama fiyat hedefi 8,00-9,00 $ aras\u0131, %400-455 y\u00fckseli\u015f potansiyeli (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/CRDL\/forecast\/\">Analist Hedefleri<\/a>)<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Kardiyovask\u00fcler inflamasyon tedavilerine artan odaklanma<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc Y\u00f6netim<\/strong>: Son hissedar oylamalar\u0131nda t\u00fcm y\u00f6netim kurulu adaylar\u0131 %92&#8217;nin \u00fczerinde onay ald\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2>\n<p><strong>\u015eu anda ne yapmal\u0131s\u0131n\u0131z?<\/strong> \u0130\u015fte profesyonel tavsiyem:<\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-3&#8217;\u00fcn\u00fc CRDL&#8217;ye ay\u0131r\u0131n\u2014bu y\u00fcksek riskli bir biyoteknoloji yat\u0131r\u0131m\u0131d\u0131r<\/li>\n<li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: Giri\u015f fiyat\u0131n\u0131z\u0131 ortalamak i\u00e7in birka\u00e7 hafta i\u00e7inde par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li>\n<li><strong>Zarar Durdur Emirleri Koyun<\/strong>: Sermayenizi korumak i\u00e7in %15-20 zarar durdur emirleri belirleyin<\/li>\n<li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: Kas\u0131m kazan\u00e7lar\u0131 ve klinik deneme g\u00fcncellemelerini izleyin<\/li>\n<\/ol>\n<p><strong>Esprili deneyimli yat\u0131r\u0131mc\u0131 bilgeli\u011fi<\/strong>: &#8220;CRDL gibi biyoteknoloji hisseleriyle i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar, aralarda radyo sessizli\u011fi ve ara s\u0131ra patlay\u0131c\u0131 tepkiler. Her zaman acil \u00e7\u0131k\u0131\u015f stratejiniz olsun!&#8221;<\/p>\n<h2>\u2705 Ad\u0131m Ad\u0131m: Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeleri ve biyoteknoloji hisseleri sunan bir platform se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Do\u011frulamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Uyumluluk i\u00e7in gerekli belgeleri sa\u011flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td>\n<td>Risk alabilece\u011finiz y\u00f6netilebilir bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>CRDL&#8217;yi \u0130yi Ara\u015ft\u0131r\u0131n<\/td>\n<td>\u015eirketin \u00fcr\u00fcn hatt\u0131n\u0131 ve risklerini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Limit Emri Verin<\/td>\n<td>Fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Pozisyonunuzu Takip Edin<\/td>\n<td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>D\u00fczenli Olarak G\u00f6zden Ge\u00e7irin<\/td>\n<td>Yat\u0131r\u0131m tezini \u00fc\u00e7 ayda bir yeniden de\u011ferlendirin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option&#8217;\u0131n \u00dcst\u00fcnl\u00fckleri<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, CRDL gibi hisselerde i\u015flem yapmak i\u00e7in ola\u011fan\u00fcst\u00fc avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $\u2014stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Herhangi bir resmi kimlik ile 1 dakikal\u0131k KYC s\u00fcreci<\/li>\n<li><strong>\u00c7ekim Se\u00e7enekleri<\/strong>: Kripto, e-c\u00fczdanlar ve banka kartlar\u0131 dahil 100&#8217;den fazla y\u00f6ntem<\/li>\n<li><strong>Kullan\u0131c\u0131 Dostu Platform<\/strong>: Yeni ba\u015flayanlar i\u00e7in tasarlanm\u0131\u015f sezgisel aray\u00fcz<\/li>\n<li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: Pocket Option blogunda kapsaml\u0131 \u00f6\u011frenme materyalleri<\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, biyoteknoloji hisse ticaretinin inceliklerini \u00f6\u011frenirken k\u00fc\u00e7\u00fck ba\u015flay\u0131p b\u00fcy\u00fcmek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Cardiol Therapeutics: Yenilik Lideri<\/h2>\n<p>Cardiol Therapeutics, kardiyovask\u00fcler t\u0131p yenili\u011finin \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirket, milyonlarca insan\u0131 etkileyen ve s\u0131n\u0131rl\u0131 tedavi se\u00e7ene\u011fi bulunan kalp hastal\u0131klar\u0131 i\u00e7in anti-inflamatuar ve anti-fibrotik tedaviler geli\u015ftirmeye odaklan\u0131yor.<\/p>\n<p><strong>Mevcut Odak Alanlar\u0131<\/strong>:<\/p>\n<ul>\n<li>Akut miyokardit ve tekrarlayan perikardit i\u00e7in CardiolRx\u2122<\/li>\n<li>Kalp yetmezli\u011fi i\u00e7in CRD-38 subkutan form\u00fclasyon<\/li>\n<li>Nadir kardiyak durumlar i\u00e7in yetim ila\u00e7 stat\u00fcs\u00fcndeki tedaviler<\/li>\n<\/ul>\n<p>\u015eirketin yak\u0131n zamanda tamamlanan Faz II ARCHER denemesi, FDA onayl\u0131 tedavisi olmayan akut miyokarditte umut verici etkinlik g\u00f6sterdi (<a href=\"https:\/\/thedeepdive.ca\/cardiol-therapeutics-releases-positive-topline-results-from-phase-ii-clinical-trial\/\">Klinik Geli\u015fim<\/a>). Bu, Cardiol&#8217;u hizmet verilmeyen bir pazarda potansiyel lider olarak konumland\u0131r\u0131yor.<\/p>\n<p><strong>\u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: 2025 y\u0131l\u0131nda Cardiol Therapeutics, k\u00fcresel tedarik zinciri zorluklar\u0131 s\u0131ras\u0131nda \u00e7ok uluslu bir Faz II denemesini ba\u015far\u0131yla tamamlayan az say\u0131daki biyoteknoloji \u015firketinden biri oldu; ABD, Fransa, Brezilya ve \u0130srail\u2019den hastalar kaydedildi ve \u00f6nemli gecikme ya\u015fanmad\u0131\u2014bu, klinik ara\u015ft\u0131rmadaki operasyonel m\u00fckemmeliyetlerinin bir kan\u0131t\u0131d\u0131r.<\/p>\n"},"faq":[{"question":"Cardiol Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \u015firketi ara\u015ft\u0131r\u0131n, limit emri verin ve pozisyonunuzu d\u00fczenli olarak takip edin."},{"question":"Cardiol Therapeutics'in gelecekteki fiyat tahmini nedir?","answer":"2025 y\u0131l sonu hedefi 2,50-3,00 $, 2026 tahmini 4,00-5,00 $, 2028 projeksiyonu 6,00-8,00 $ ve 2030 uzun vadeli vizyon 10,00 $ ve \u00fczeridir."},{"question":"Cardiol Therapeutics yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, nakit t\u00fcketimi, reg\u00fclasyon engelleri, piyasa volatilitesi ve hisse seyrelme riski ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar i\u00e7in Cardiol Therapeutics hisselerinde i\u015flem yaparken ne \u00f6nerilir?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fc ile k\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyeti ortalamas\u0131 yap\u0131n, zarar durdur emirleri koyun ve \u00f6nemli kataliz\u00f6rleri takip edin."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7ok say\u0131da \u00e7ekim se\u00e7ene\u011fi, kullan\u0131c\u0131 dostu platform ve kapsaml\u0131 e\u011fitim kaynaklar\u0131 sunar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Cardiol Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \u015firketi ara\u015ft\u0131r\u0131n, limit emri verin ve pozisyonunuzu d\u00fczenli olarak takip edin."},{"question":"Cardiol Therapeutics'in gelecekteki fiyat tahmini nedir?","answer":"2025 y\u0131l sonu hedefi 2,50-3,00 $, 2026 tahmini 4,00-5,00 $, 2028 projeksiyonu 6,00-8,00 $ ve 2030 uzun vadeli vizyon 10,00 $ ve \u00fczeridir."},{"question":"Cardiol Therapeutics yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, nakit t\u00fcketimi, reg\u00fclasyon engelleri, piyasa volatilitesi ve hisse seyrelme riski ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar i\u00e7in Cardiol Therapeutics hisselerinde i\u015flem yaparken ne \u00f6nerilir?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fc ile k\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyeti ortalamas\u0131 yap\u0131n, zarar durdur emirleri koyun ve \u00f6nemli kataliz\u00f6rleri takip edin."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7ok say\u0131da \u00e7ekim se\u00e7ene\u011fi, kullan\u0131c\u0131 dostu platform ve kapsaml\u0131 e\u011fitim kaynaklar\u0131 sunar."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T13:58:46+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T13:58:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\",\"name\":\"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"datePublished\":\"2025-08-25T13:58:46+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T13:58:46+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T13:58:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/","name":"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","datePublished":"2025-08-25T13:58:46+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":348132,"slug":"how-to-buy-cardiol-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Cardiol Therapeutics Inc. (CRDL) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Cardiol Therapeutics Inc. (CRDL)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":348129,"slug":"how-to-buy-cardiol-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Cardiol Therapeutics Inc. (CRDL) - Investimento em a\u00e7\u00f5es da Cardiol Therapeutics Inc. (CRDL)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=348131"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348131\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334126"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=348131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=348131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=348131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}